Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Disc Medicine, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Disc Medicine, Inc. (“Disc Medicine” or “the Company”) (NASDAQ: IRON). Investors who purchased Disc Medicine securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Disc Medicine has violated federal securities laws.
Disc Medicine Investigation Details
On February 13, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine’s new drug application (“NDA”) as there were uncertainties in the NDA that would need additional evidence. Following this news, Disc Medicine’s stock price fell 22% on February 13, 2026.
What’s Next for Disc Medicine Investors?
If you are aware of any facts relating to this investigation or purchased Disc Medicine securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
IRON — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”